A global shortage of hepatitis B vaccine has developed as both Merck & Co. and GlaxoSmithKline deal with manufacturing issues.

Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.

The FDA is asking for more details about Heplisav-B's postmarketing surveillance plan, but Dynavax executives and analysts said they remain confident.

Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.

At Dynavax’s third try, an FDA panel favored hepatitis B candidate Heplisav-B's safety profile by a vote of 12 to 1.

J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.

On the heels of new genital herpes data, one analyst believes things may get a whole lot better at Genocea.

Novavax's shares slid 19% after topline data from a new phase 2 trial on its RSV vaccine fail to impress investors.